Stocks To Watch For Wednesday 02/26/14 – FNMA WPWR ONCS


Hi Everyone & Welcome New Subscribers,

FNMA and WPWR combined for gains of more than 30% collectively at today’s close, which made for a great day if you played either of them after our heads up on last night’s list. They’re going to be on top of our watch tomorrow for even more gains too.

FNMA – Potential Continue Breakout – (Fannie Mae) – closed up 12.85%, at $4.04, on more than 41.3 million shares traded Tuesday. Fannie Mae is a government-sponsored enterprise that was chartered by Congress in 1938 to support liquidity, stability and affordability in the secondary mortgage market, where existing mortgage-related assets are purchased and sold. Shares of FNMA closed over $4.00 today, a level we suspect it might test/break this week, and has it’s sight set on even higher ground tomorrow. Volume wasn’t as strong Tuesday, however, as it was Monday, which could equate to profit taking after some early momentum Wednesday. This should be a good one to keep an eye on after a day or two of downside following this rally for a ‘buy on the dip’. Keep it on close watch.

WPWR  Promotion/Continued Momentum/Breakout – (Well Power, Inc.) – closed up 21.57%, at .62 a share, on more than 10 million shares traded Tuesday. Well Power Inc has secured the licensing rights to Texas with the first right of refusal on other US states to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels. WPWR saw more nice gains today, just as we thought it might, closing over the .60 level today just off it’s new high of .6235. Can WPWR get to .75 or .80 tomorrow? Keep it on close watch.

ONCS – Potential Continued Breakout – (OncoSec Medical) – closed up 23.43%, at .696 a share, on more than 14.3 million shares traded Tuesday. OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immunocytokines. Shares of ONCS continued higher today in a big way, with more money flowing through the stock than ever before, as shares reached a high of .71 today before meeting resistance. ONCS may test .80 early tomorrow before seeing anymore resistance, but will need to break above .71 first. Over the next few weeks, it doesn’t seem like a $1.00 or higher price tag is an unrealistic target. Keep it on close watch.

New Profiled Pick Coming Soon: Most Recent Pick Surged Nearly 40% From Our Alert On Record Volume! 

Sign Up-> HERE <-To Be Among The First To Receive Our Next Winning Pick!

Happy Trading!

The Penny Stock Experts Team at

Follow us on Twitter @Todayspickis

Please read our legal Disclaimer below:

This disclaimer is to be read in its entirety, and fully understood before using or joining the email list. reserves the right to revise, amend, or modify our Privacy Policy, our Disclaimer, and our other policies and agreements at any time and in any manner by updating their postings. You are responsible for regularly reviewing these terms, conditions, and notices, and any additional terms posted on Your continued use of the website and/or email newsletter after the effective date of such changes constitutes your acceptance of and agreement to such changes. If we should update this disclaimer, we will post the updates to this page on

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS.Neither nor any of its employees, affiliates, subsidiaries, or family members are registered investment advisers or registered stock brokers either within the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority and shall not be liable for any direct, indirect, incidental, special or consequential damages arising out of, or resulting from the use or inability to use this site, including but not limited to damages for the loss of capital, funds, profits, use, data, or any and all other possible damages, even if such party has been advised of the possibility of such damages resulting from the use of this site and all information contained on this site. We are neither licensed nor qualified to provide investment advice.

The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the company’s profiled based solely on information contained in our newsletter or website. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research. may buy or sell shares on the open market that may positively or negatively affect the stock price before or after this mailing and subscribers are to be fully aware that and it’s affiliates can buy or sell more shares at any time. and/or it’s affiliates may receive compensation for e-mail alerts. To view our full compensation disclosure please visit does not accept free-trading shares as a form of payment.